FDA Approves First-In-Class IL-6R Inhibitor as The First And Only At-Home Subcutaneous Treatment Option For Thyroid Eye Disease (TED)
October 15th, 2026
On October 15, 2026, the FDA approved Genentech’s Enspryng® (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED). Enspryng is the first and only at-home subcutaneous treatment option approved in the U.S. for the treatment of TED.
News in brief
- Enspryng (satralizumab-mwge) represents an important advance for people with TED, offering the first at-home subcutaneous (SC) treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered
- The approval is based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favorable safety profile, regardless of TED activity or duration
- Enspryng is an anti-interleukin-6 receptor (IL-6R) monoclonal antibody (mAb) using novel recycling antibody technology designed to inhibit IL-6 signaling upstream of autoantibody-driven pathology
- TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people in the U.S. that can lead to facial disfigurement and vision-threatening complications if left untreated
Supporting Information
“Today’s FDA approval of Enspryng provides an important new option for people with thyroid eye disease, who have long faced limited treatment choices. As the first subcutaneous treatment for this condition, Enspryng offers a positive safety and efficacy profile and the potential for at-home administration.”